1. Introduction {#sec1-genes-08-00127}
===============

Ankylosing spondylitis (AS) is a progressive and debilitating seronegative spondiloarthritis, involving primarily the sacro-iliac joints and the spine and frequently the peripheral joints. Extra-articular tissues involvement, such as skin, tendons or eyes is often present \[[@B1-genes-08-00127]\]. AS has a strong genetic background being associated with the major histocompatibility complex (MHC) class I allele HLA-B27 in more than 90% of the patients \[[@B2-genes-08-00127]\].

The disease prevalence ranges the 0.02%--0.35% depending on the race, with a higher prevalence in males than in females \[[@B1-genes-08-00127]\].

According to the Assessment of SpondyloArthritis International Society/European League Against Rheumatism (ASAS/EULAR) and American College of Rheumatology/ Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN), there is a recommendation for patients with a predominantly active axial manifestation of AS that they should be treated for at least three months with nonsteroidal anti-inflammatory drugs (NSAIDs) followed by a tumor necrosis factor (TNF)-alpha blocker in case of non response or of NSAIDs-related side effects, while patients with both axial and peripheral involvement need treatment with TNF-blockers and eventually with disease-modifying antirheumatic drugs (DMARDS) in case of intolerance or controindication to anti-TNF-alpha treatment \[[@B3-genes-08-00127],[@B4-genes-08-00127]\].

Treatment with the TNF blockers, infliximab, etanercept, adalimumab, golimumab and certolizumab, leads to a good improvement in clinical symptoms, in C-reactive protein (CRP) levels and in magnetic resonance imaging (MRI)-detectable inflammation of the sacroiliac joints \[[@B5-genes-08-00127]\].

In particular, Adalimumab (ADA) is a humanized monoclonal antibody against TNF-alpha, able to block both monomeric and trimeric soluble forms of TNF-alpha and cell-surface TNF-alpha, inducing cell apoptosis.

In this work, we have analyzed the transcriptome of Peripheral Blood Cells (PBCs) from patients with AS in order to identify possible mechanisms involved in the pathogenesis of the disease.

Previous studies on gene expression analyses in PBCs have identified gene signatures specifically associated to several diseases including Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) \[[@B6-genes-08-00127],[@B7-genes-08-00127]\]. Moreover, in a previous work on microarray analysis in Psoriatic Arthritis (PsA), we analyzed Differentially expressed genes (DEGs) in PBCs and in cells derived from synovial biopsies, and found that gene expression profiles of the cells obtained from the inflamed synovium are similar to those of PBCs, indicating that PBCs can be a good substitute of the target tissues to analyze disease-associated gene expression \[[@B8-genes-08-00127]\].

High-throughput methodologies, including microarray, have increased our understanding of many diseases. However, while several studies on gene array analyses revealed transcriptional profiles of many single genes differentially expressed in AS compared to healthy subjects, such studies have not analyzed gene product interactions and molecular pathways possibly related to the disease onset. A careful evaluation of such networks can provide a deeper insight in the understanding of disease pathogenesis. In this study, we implemented the gene-array study with networks and modules analyses to uncover possible molecular pathways associated to AS and to a good response to ADA therapy.

This is indeed a novel approach since other studies used a conventional gene expression analysis to study, at gene level, the response to TNF inhibitors in rheumatoid arthritis \[[@B9-genes-08-00127],[@B10-genes-08-00127]\] and to our knowledge, there are no such studies of ankylosing spondylitis.

In AS we found deregulated genes that are involved in important pathways; moreover, such genes are differently modulated in patients that show a good response to treatment compared to non-responders. Interestingly, in patients with a good response to treatment, we also observed that ADA normalized the altered expression of genes involved in AS-associated pathways.

2. Materials and Methods {#sec2-genes-08-00127}
========================

2.1. Patients {#sec2dot1-genes-08-00127}
-------------

We studied a cohort of ten patients (seven males and three females, mean age: 51.8 years) affected by Ankylosing spondylitis (AS), attending the Unit of Autoimmune Diseases, at the University Hospital of Verona, Italy. A written informed consent was obtained from all the partecipants to the study. The study was approved by the local Ethical Committee and all clinical investigations have been conducted according to the principles expressed in the Helsinki declaration.

All patients fulfilled the modified New York criteria for the diagnosis of AS which included radiological and clinical criteria represented by (1) radiological evidence of sacroileitis; (2) low back pain and stiffness standing for at least three months, improved by exercise and not relieved by rest; (3) decrease of lumbar spine motility in both sagittal and frontal planes; and (4) limitation of chest expansion \[[@B11-genes-08-00127],[@B12-genes-08-00127]\].

The patients underwent clinical examination and laboratory evaluation, which included inflammatory markers, such as erytrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and genetic screening for the association with the allele HLA-B27. All patients underwent conventional radiography, magnetic resonance imaging (MRI) for the axial and peripheric involvement of the arthropathy. All patients were treated with the same anti-TNF agent Adalimumab, and samples for the gene array analysis were collected before and seven days after the anti-TNF injection. Adalimumab was administrated every two weeks without any side effects. The clinical features of the patients are reported in [Supplementary Materials Table S1](#app1-genes-08-00127){ref-type="app"}.

The evaluation of responder and non-responder patients to the treatment was carried out according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI score), defining remission when the score is less than 3.8 \[[@B13-genes-08-00127]\].

Ten healthy age and sex matched healthy subjects were used as controls.

2.2. Gene Array {#sec2dot2-genes-08-00127}
---------------

Blood samples were collected using PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) and total RNA was extracted following the manufacturer instructions. cRNA preparation, samples hybridization and scanning were performed following the Affymetrix (Affymetrix, Santa Clara, CA, USA) provided protocols, by Cogentech Affymetrix microarray unit (Campus IFOM IEO, Milan, Italy). Human Genome U133A 2.0 (HG-U133A 2.0) Gene Chip (Affymetrix) were used. The HG-U133A 2.0 Gene Chip covers more than 22,000 probe sets corresponding up to 14,500 well-characterized human genes. The microarray analysis was carried out using the Gene Spring software, version 12.5 (Agilent Technologies, SantaClara, CA, USA) selecting the Robust Multi-Array Average algorithm (RMA) to background-adjust, normalize, and log-transform signals intensity. As the log~2~ scale was used, a signal log~2~ ratio of 1.0 corresponds to a transcript level increase of two-fold change (2 FC) and −1.0 a lowering of two-fold change (−2 FC). A signal log~2~ ratio of zero indicates no change. Relative gene expression levels of each transcript were validated applying the unpaired *t*-test (*p* ≤ 0.01) and the Bonferroni multiple testing correction. Genes that displayed an expression level at least 1.5 fold different in the test sample versus control sample (*p* ≤ 0.01) were submitted both to functional classification, using the Gene Ontology (GO) annotations, and to Pathway analysis, employing the Panther expression analysis tools (<http://pantherdb.org/>) \[[@B14-genes-08-00127]\]. The enrichment of all pathways and functional classes associated to the differentially expressed genes compared to the distribution of genes included on the Affymetrix HG-U133A microarray was analyzed and *p* values ≤ 0.05, calculated by the binomial statistical test were considered as significant enrichment.

2.3. Protein-Protein Interaction (PPI) Network Construction and Network Clustering {#sec2dot3-genes-08-00127}
----------------------------------------------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING version 1.0; <http://string-db.org/>) is a web-based database which comprises experimental as well as predicted interaction informations and covers \>1100 completely sequenced organisms \[[@B15-genes-08-00127]\]. DEGs were mapped to the STRING database to detect protein-protein interactions (PPI) pairs that were validated by experimental studies or retrieved by text mining and homology analysis \[[@B16-genes-08-00127]\]. A score of ≥0.7 for each PPI pair was selected to design the PPI network.

The graph-based Markov Clustering algorithm (MCL) allows to visualize high-flow areas (the clusters) \[[@B17-genes-08-00127]\]. In order to detect highly connected regions, the MCL algorithm was applied.

Cytoscape software \[[@B18-genes-08-00127]\] was used to define the topology of the builded networks.

2.4. Real Time RT-PCR {#sec2dot4-genes-08-00127}
---------------------

Total RNA was isolated from PBC using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), following manufacturer's instructions. First-strand cDNA was generated using the SuperScript III First-Strand Synthesis System for RT-PCR Kit (Invitrogen), with random hexamers, according to the manufacturer's protocol. PCR was performed in a total volume of 25 μL containing 1× Taqman Universal PCR Master mix, no AmpErase UNG and 2.5 μL of cDNA; pre-designed, Gene-specific primers and probe sets for each gene (IL6ST, TNFRSF25, TNFSF8, and STAT1) were obtained from Assay-on-Demand Gene Expression Products (Applied Biosystems, Foster, CA, USA). As described in detail previously \[[@B19-genes-08-00127],[@B20-genes-08-00127],[@B21-genes-08-00127]\], Real Time PCR reactions were carried out in a two-tube system and in singleplex. The Real Time amplifications included 10 min at 95 °C (AmpliTaq Gold activation, Thermo Fisher Scientific, Waltham, MA, USA), followed by 40 cycles at 95 °C for 15 s and at 60 °C for one minute. Thermocycling and signal detection were performed with 7500 Sequence Detector (Applied Biosystems). Signals were detected according to the manufacturer's instructions. This technique allows the identification of the cycling point where PCR product is detectable by means of fluorescence emission (Threshold cycle or *C*~t~ value). As previously reported, the *C*~t~ value correlates to the quantity of target mRNA \[[@B22-genes-08-00127]\]. Relative expression levels were calculated for each sample after normalization against the housekeeping genes GAPDH, beta-actin and 18 s ribosomal RNA (rRNA), using the ΔΔ*C*~t~ method for comparing relative fold expression differences \[[@B19-genes-08-00127],[@B23-genes-08-00127]\]. The data are expressed as fold change. *C*~t~ values for each reaction were determined using TaqMan SDS analysis software. For each amount of RNA tested triplicate *C*~t~ values were averaged. Because *C*~t~ values vary linearly with the logarithm of the amount of RNA, this average represents a geometric mean.

3. Results {#sec3-genes-08-00127}
==========

In order to identify gene expression profiles associated with AS, we compared the gene expression profiles of PBC samples obtained from 10 AS patients before treatment with ADA with 10 PBC samples obtained from healthy age and sex matched donors.

We found that 740 modulated transcripts satisfied the Bonferroni--corrected *p* value criterion (*p* ≤ 0.01) and the fold change criterion (FC ≥ \|1.5\|), showing robust and statistically significant variation between AS and healthy controls samples. In particular, 615 and 125 transcripts resulted to be over- and underexpressed respectively. The complete list of modulated genes can be found in [Supplementary Materials Table S2](#app1-genes-08-00127){ref-type="app"}.

The Gene Ontology analysis showed that a large number of the modulated transcripts can be ascribed to biological processes that may play a role in AS, including: cell proliferation, extracellular matrix organization, angiogenesis, immune response, inflammatory response, interleukin-6 production, ossification, bone remodeling and signal transduction. Among these processes we noticed that signal transduction and immune response were the most represented biological processes. We also observed that immune response encompassed several Th-17-related genes including CD28 molecule, CD3 molecule epsilon (CD3E) and gamma (CD3G) subunits, CD4 molecule, transforming growth factor beta 1 (TGFB1), interleukin 6 receptor (IL6R), interleukin 6 signal transducer (IL6ST).

The signal transduction functional class included genes that may be ascribed to different subcategories including: inflammation mediated by chemokine and cytokine signaling pathway, Jak-Stat signaling pathway, Wnt signaling pathway, mirogen-activated protein kinase (MAPK) cascade, tumor necrosis factor-mediated signaling pathway, TLR signaling pathway, cytokine-mediated signaling pathway, Type I interferon signaling pathway, fibroblast growth factor receptor signaling pathway, T-cell receptor signaling pathway, small GTPase mediated signal transduction, transforming growth factor (TGFB) signaling, Notch signaling and phosphatidylinositol-mediated signaling.

[Table 1](#genes-08-00127-t001){ref-type="table"} and [Table 2](#genes-08-00127-t002){ref-type="table"} show a detailed selection of DEGs within the above-mentioned processes. The tables also include GeneBank accession numbers and fold changes.

The modulation of some genes observed by gene array analysis was validated by Q-PCR ([Figure 1](#genes-08-00127-f001){ref-type="fig"}).

Given the high number of DEGs and the corresponding functional classes, to make our study more informative, we decided to complement the gene expression profiling of AS PBC with the study of functional interactions between the protein products of modulated genes. To this aim, a protein-protein interaction (PPI) network comprising 401 genes (nodes) and 1345 pairs of interactions (edges) was obtained ([Figure 2](#genes-08-00127-f002){ref-type="fig"}A). In [Figure 2](#genes-08-00127-f002){ref-type="fig"}B the interconnected genes are represented in a circular graph and are ordered based on their degree of connectivity, so genes with a similar degree of connectivity are placed close to each other. We then submitted the PPI network to a modular analysis to find set of densely interconnected nodes (modules) that are expected to participate in multiple biological activities in a coordinated manner. We identified eight modules (*k* = 5) that are graphically represented in [Figure 2](#genes-08-00127-f002){ref-type="fig"}C. [Figure 2](#genes-08-00127-f002){ref-type="fig"}B shows that the genes belonging to the eight modules (highlighted in red) are distributed (concentrated) over an area in which the highest degrees of connectivity are present, thus confirming that they are highly connected genes.

We next performed functional enrichment analysis to identify association of genes, in each module, with different "GO terms" and pathways. All the significantly enriched categories for each module are shown in [Supplementary Materials Table S3](#app1-genes-08-00127){ref-type="app"} and included pathogenetically relevant processes such as: T-cell receptor signaling (module M3), TLRs signaling (modules M3 and M7), small GTPase signaling (module M3) Wnt signaling (module M7), p38 MAP kinase cascade (modules M3 and M6) Jak-stat signaling (module M3) fibroblast growth factor receptor signaling (module M3) inflammation mediated by chemokine and cytokine signaling pathway (modules M3 and M7) VEGF signaling (modules M3 and M6) angiogenesis (module M3).

In order to evaluate the effect of treatment on gene expression in AS patients, we analysed the transcriptional profiles obtained from the same AS patients seven days after ADA administration.

When the same Bonferroni-corrected *p* value and fold change criteria were applied, 571 genes were differentially expressed in AS patients after treatment compared to healthy controls, in particular 492 and 79 transcripts resulted to be up- and down-regulated respectively ([Supplementary Materials Table S4](#app1-genes-08-00127){ref-type="app"}). The protein products of 297 DEGs, among the above mentioned genes, were connected in a PPI network involving 819 pairs of interactions ([Figure 3](#genes-08-00127-f003){ref-type="fig"}), from which 7 modules can be extracted.

We next performed GO biological process and pathways enrichment analysis of genes included in the seven modules. Modules and the resulting enriched functional categories are listed in [Supplementary Materials Table S5](#app1-genes-08-00127){ref-type="app"}.

Afterwards, we compared the lists of processes enriched in modules from the two analysis (samples before treatment versus healthy controls and samples after treatment versus healthy controls) and we found that several pathways and biological processes were enriched only in the pre-treatment associated modules ([Table 3](#genes-08-00127-t003){ref-type="table"}).

In particular, we found that after treatment the enrichment in p38 MAPK (*p* value = 0.007), P53 pathway feedback loops 1 (*p* value = 0.005), PI3 kinase pathway (*p* value = 0.015) and Wnt signaling pathways (*p* value \< 0.001) disappeared. In addition, we observed that all pathways that showed an enrichment only in the pre-treatment condition were associated to the pre-treatment associated modules M3, M6 and M7.

Many biological processes were also influenced by the therapy, since they were no longer enriched after treatment. These processes were associated to the pre-treatment module M3 and included: fibroblast growth factor receptor signaling (*p* value \< 0.001), small GTPase mediated signal transduction (*p* value = 0.040), immune effector process (*p* value = 0.007), leukocyte migration (*p* value = 0.032), positive regulation of T-cell proliferation (*p* value = 0.035), response to interleukin-2 (*p* value = 0.001), T-cell costimulation (*p* value \< 0.001), T-cell differentiation (*p* value = 0.015), T-cell receptor signaling (*p* value \< 0.001), and phosphatidylinositol-mediated signaling pathway (*p* value = 0.002).

Although the patients enrolled in the study were homogeneous as far as clinical features and stage of the disease concern, we could identify two groups who showed a different response to treatment.

The first group (group 1) consisted of 6 patients who had a very good response to the treatment with disease remission and the second group (group 2) of four patients who showed a poor response to the treatment.

We then performed a gene array analysis by dividing patients in two groups, according to their response to the treatment, and comparing the expression profiles of two groups, before and after treatment, to those of the healthy control samples.

Before treatment we observed that in the first group of patients 689 genes, and in the second group 987 genes were modulated ([Supplementary Materials Tables S6 and S7](#app1-genes-08-00127){ref-type="app"}). After treatment, a modulation of 846 transcripts in the first group of patients and of 1077 genes in the second group was observed compared to the control group ([Supplementary Materials Tables S8 and S9](#app1-genes-08-00127){ref-type="app"}). When we compared genes modulated pre- and post-treatment in the two groups, we observed that 306 genes in the first group and 119 genes in the second group, returned to baseline expression levels after treatment, showing an expression level comparable to that of healthy controls.

To finely dissect the effect of ADA treatment on gene expression profiles in the two patients groups, we decided to functionally analyze these genes and we found that ADA had an impact on genes involved in signaling events that may be related to the pathogenesis of the disease. In particular, we compared the two lists of biological signaling in which DEGs, that were corrected by the treatment, were involved ([Table 4](#genes-08-00127-t004){ref-type="table"}).

We found that some of these categories were shared by the two groups of patients, (i.e., immune response, inflammatory response, angiogenesis, MAP kinase, Jak-Stat small GTPase, T-cell receptor, Notch and TGF-beta signaling) while others were only associated to group 1 (i.e., interleukin 6 production, cytokine mediated, NIK/NF-Kappa B, Toll-like receptor, Tumor necrosis factor, Type 1 interferon, and Wnt signaling) or to group 2 (i.e., EGF receptor, Ephrin receptor, Fc-gamma receptor signaling and positive regulation of BMP and VEGF signaling).

A selection of the above-mentioned genes, which were corrected by the treatment in the two groups of patients, referred to as "genes modulated only before treatment is reported in [Table 5](#genes-08-00127-t005){ref-type="table"} and [Table 6](#genes-08-00127-t006){ref-type="table"}, where transcripts are grouped according to the Gene Ontology classification criteria. These tables also show the fold changes resulting from the comparison of pre- or post-treatment condition versus healthy controls.

Then we also performed a functional enrichment analysis to detect biological processes that were significantly enriched in genes corrected by the treatment.

Some of the enriched biological classes were related to the immune response and, in particular, to the activation of B and T-cell response, as indicated by the enrichment in T-cell activation (*p* value = 0.005), positive regulation of B-cell activation (*p* value = 0.041) and B-cell cytokine production (*p* value = 0.024) categories in the first group, and by the enrichment in T-cell activation (*p* value = 0.038) and positive regulation of B-cell activation (*p* value = 0.015) classes in the second group ([Table 7](#genes-08-00127-t007){ref-type="table"}). Genes involved in inflammation were also well represented in the two datasets modulated only before treatment and the two classes "inflammatory response" (*p* value = 0.026) and "NLRP3 inflammasome complex assembly" (*p* value = 0.006) were enriched in the first and in the second group, respectively.

In addition, we also identified functional classes that were enriched only in one of the two groups of patients. These classes were: positive regulation of cytokine production (*p* value = 0.012) positive regulation of type I interferon production (*p* value = 0.017) Toll-like receptor signaling pathway (*p* value = 0.039) positive regulation of interleukin-2 production (*p* value = 0.001) cellular response to unfolded protein (*p* value = 0.001) in the first group and, angiogenesis (*p* value = 0.002) response to transforming growth factor beta (*p* value = 0.010) and G-protein coupled receptor signaling pathway (*p* value = 0.031) in the second group.

4. Discussion {#sec4-genes-08-00127}
=============

In this work, we first compared the gene expression profiles of 10 AS patients before treatment with 10 healthy controls. Secondly, we analysed the gene expression before and after ADA therapy, in order to identify biological processes that may be modulated by the drug. Finally, we compared gene profiles of patients characterized by a different response to the treatment.

Our results showed that AS has a profound impact on gene expression, since a large number of genes are modulated in AS samples. Moreover, DEGs have a role in biological processes that may be pathogenetically relevant to both the disease onset and progression.

The pathological features of AS are supposed to originate from several events that may interact, including biomechanical insult, genetic background, infections, inflammation and immune response, even though the precise mechanisms of the immune activation are still a matter of discussion \[[@B24-genes-08-00127]\].

We here identified a large number (40) of genes that have well-documented roles in the immune response, including for example TNFSF8/CD30L, interleukin-32 and several Th17-lymphocytes-related genes. TNFSF8 is a TNF-family member expressed on activated peripheral blood T-cells, B-cells, neutrophils, mast cells, monocytes, and macrophages and it is the ligand for CD30, a molecule that is present at high levels in AS patients compared to healthy controls \[[@B25-genes-08-00127]\]. The CD30/CD30L signaling system has been implicated in the pathogenesis of several autoimmune and inflammatory diseases and it has been recently associated to the pathogenesis of rheumatoid arthritis synovitis \[[@B26-genes-08-00127]\].

Interleukin-32 is a proinflammatory cytokine produced by T lymphocytes, natural killer cells, blood monocytes and fibroblast-like synoviocytes in the joints. It is present in the synovial fluid of AS patients at higher levels compared with RA or osteoarthritis patients and induces osteoblast differentiation leading to pathological bone growth \[[@B27-genes-08-00127]\].

Th17 cells have been associated to several autoimmune disorders including SLE, RA and psoriasis where they play a role in the pathogenesis of the disease \[[@B28-genes-08-00127],[@B29-genes-08-00127],[@B30-genes-08-00127]\]. Recent studies have demonstrated that Th17 cells are involved also in the pathogenesis of AS \[[@B31-genes-08-00127]\].

It is well known that the pathogenesis of AS is characterized by three phases: inflammation, erosion and abnormal bone outgrowth \[[@B32-genes-08-00127]\]. In this regard our data seem to recapitulate all these pathogenetic stages, showing deregulation of genes involved in the inflammatory process as well of transcripts that play a role in bone remodeling (i.e., bone growth and bone erosion).

Although the precise events that prime inflammation in spondyloarthritis is still unclear, recent findings provided evidence of the involvement of immune pathways, including the lately described IL-17/IL-23 pathway, NF-κB activation and antigen presentation \[[@B33-genes-08-00127]\] reintroducing the issue of autoimmune versus autoinflammatory disease. To date, however, no immunological pathway has emerged as the master regulator that may finely orchestrate the disease pathogenesis.

Interestingly, we found a remarkable number of DEGs included genes acting in commonly known immunological signalings such as TNF, MAP kinase cascade, Wnt, Toll-like receptor, TGF beta, T-cell receptor, Type I interferon, and Jak-stat signaling.

TNF-alpha is one of the main actors in the inflammatory scenario during the disease progression. Interestingly, here we show up-regulation of several genes involved in the TNF-alpha signaling including TNFRSF25. This molecule is a tumor necrosis factor receptor mainly expressed on T-cells \[[@B34-genes-08-00127]\] that has been associated with autoimmune diseases such as RA. Moreover, it has been reported that the absence of TNFRSF25 protects from the development of severe bone disorders in experimental antigen-induced arthritis (AIA) \[[@B35-genes-08-00127]\]. Along with the upregulation of TNF-related genes we also found overexpression of genes involved in interleukin-6 production and signal transduction (including IL6R and IL6ST) together with overexpression of transcripts of the MAP kinases cascade, two well-documented down-stream events of the biologic response to TNF \[[@B36-genes-08-00127]\]. In particular, it has been shown that high serum levels of IL-6 may associate with the development of AS \[[@B36-genes-08-00127]\]. The triggering of mitogen-activated kinase (MAPK) signaling cascade leads to activation of downstream JUN N-terminal kinase (JNK) and p38/MAPK14 \[[@B37-genes-08-00127]\], which is involved in the proinflammatory activity of interleukin 1 (IL-1) and TNF-alpha \[[@B38-genes-08-00127]\]. The transcript for this kinase was 1.8 fold increased in AS samples. Interestingly, it has been shown that inhibition of p38 can restore chondrocyte proliferation in inflammatory bone diseases such as spondyloarthritis \[[@B38-genes-08-00127]\].

The Wnt signaling components are critically involved in normal bone homeostasis, and in particular in new bone formation \[[@B32-genes-08-00127]\]. Moreover, it has been recently suggested that Wnt signaling may take part to the process of ankylosis in spondyloarthritis \[[@B32-genes-08-00127]\].

Deregulation of TLR signaling has been already described in AS \[[@B39-genes-08-00127]\] and there is emerging evidence of a potential role of TLRs in AS \[[@B40-genes-08-00127]\].

The up-regulation of genes involved in TGF-beta signaling is not surprising, since TGF-beta is important for bone formation and has been detected in biopsy specimens from sacroiliac joints of patient with AS where it may play a role in articular cartilage fibrosis and ossification \[[@B41-genes-08-00127]\]. Moreover, this cytokine is also involved in adaptive immune responses by regulating effector and regulatory CD4^+^ T-cell responses \[[@B42-genes-08-00127]\]. The importance of T-cell response is highlighted in our AS samples by the up-regulation of several T-cell related genes involved in T-cell receptor signaling including CD3g molecule, gamma (CD3G) and T-cell receptor alpha constant (TRAC). In particular, the association of this signaling pathway with AS has been already suggested by Chen et al. in a previous whole-blood gene expression study \[[@B43-genes-08-00127]\]. Among the modulated genes, we also found overexpression of transcripts for members of type I IFN signaling, a network typically associated with autoimmune diseases such as SLE, RA, Crohn's disease and Sjogren syndrome \[[@B44-genes-08-00127],[@B45-genes-08-00127],[@B46-genes-08-00127],[@B47-genes-08-00127],[@B48-genes-08-00127],[@B49-genes-08-00127],[@B50-genes-08-00127]\].

In this regard, the co-presence of type I IFN signaling and Th-17 related genes may be suggestive for an autoimmune origin of AS, since the co-activity of IFN and Th17 pathways is typical of autoimmunity and has been described both in human diseases and in animal models \[[@B51-genes-08-00127],[@B52-genes-08-00127],[@B53-genes-08-00127]\].

Another signaling pathway relevant to autoimmunity is the Jak-stat pathway \[[@B54-genes-08-00127]\] that is represented in our dataset by the upregulation of STAT1 and STAT5b. It has been described that STAT1 gain-of-function mutations are associated to autoimmune response \[[@B54-genes-08-00127]\] and that this molecule is differentially expressed in AS patients by transcriptome network analysis \[[@B55-genes-08-00127]\]. In addition we also found modulation of genes involved in fibroblast growth factor receptor, small GTPase and Notch signalings. It is worthwhile mentioning that the first favours the formation of new bone in AS patients \[[@B56-genes-08-00127]\], the second triggers proliferation of rheumatoid synovial fibroblasts \[[@B57-genes-08-00127]\] and the Notch signaling is involved in ligament ossification of hip joints in AS \[[@B58-genes-08-00127]\].

In the next step of our data analysis we found that DEG products were connected in a wide PPI network from which we obtained eight functional modules, containing the most functionally interconnected genes. These modules were significantly enriched in several of the above mentioned pathologically relevant processes and pathways including: T-cell receptor signaling, TLRs signaling, small GTPase signaling, Wnt signaling, p38 MAP kinase cascade and Jak-stat signaling.

Moreover, this analysis was paralleled by the comparison of post-treatment samples to healthy controls and, in this case, the resulted PPI network included seven modules.

Interestingly, by comparing pathways and biological processes enrichments of modules derived from the pre- and the post-treatment conditions, we identified three pre-treatment-associated modules (M3, M6, and M7) towards which the drug seemed to direct its activity. Indeed several crucial processes and pathways, enriched in these modules, were no longer enriched after treatment, including p38 MAP kinase, Wnt, FGF receptor, small GTPase, T-cell receptor and PI3 kinase signaling.

To more finely dissect the impact of treatment on expression profiles of AS samples, we separately analyzed the two groups of patients that were characterized by a different response to the treatment.

The two analyses showed that a quite different number of genes were modulated before treatment in the two datasets. In particular, after comparing genes modulated before and after treatment in the two groups of patients, we found a different number of genes that returned to a normal expression level after treatment.

Focusing our analysis on these genes, we realized that globally, in both groups of patients, the treatment had an impact on many pathologically relevant biological processes, including immune response, inflammatory response, angiogenesis and on several signaling pathways (i.e., Jak-Stat signaling, MAP kinase cascade and Small GTPase signaling). However we also observed that only in the responders group (group 1), genes involved in Toll-like receptor signaling, tumor necrosis factor signaling, Type I interferon signaling and Wnt signaling returned to normal.

Moreover, when we specifically analyzed the categories enriched in genes corrected by the treatment in the two groups of patients, we observed, in both data sets, an enrichment in the inflammatory response and in the lymphocytes activation processes, but we also observed that several categories were enriched only in the group 1, including regulation of interleukin-2 production, cellular response to unfolded protein, positive regulation of type I interferon production and toll-like receptor signaling.

These results suggest that the differences emerged from the separated analysis of the two groups of patients, may be partially related to the different response to treatment. In particular, we have identified altered processes and signaling that may be more strongly associated to AS pathogenesis since they are corrected by the treatment in patients with a good response.

We suggest that these biological processes may be the target of novel therapies if our results are confirmed in further experiments and in a larger number of patients.

5. Conclusions {#sec5-genes-08-00127}
==============

The etiology of AS is still unknown and the identification of the involved molecular pathogenetic pathways is a crucial issue in medicine. ADA in an humanized anti-TNF-alpha monoclonal antibody, used in the treatment of AS. Our study aimed at analyzing gene transcriptional profiles in patients with AS before and after treatment with ADA. A sophisticated analysis (i.e., PPI network clustering analysis) was used to study DEGs in AS patients before and after treatment.

By PPI network analysis it was possible to identify clusters of genes specifically associated to AS. Within these clusters DEGs belong to well known molecular pathways which play a prominent role in disease pathogenesis. Some of these pathways are strongly modified by ADA in patients with a good response to the treatment. These potentially pathogenetic pathways are not significantly modified in non responder subjects. Clustering network analysis is therefore a promising tool in gene expression studies and may help to identify new potential therapeutical targets in AS.
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![Real time (RT)-PCR of some modulated genes in AS patients. Genes selected for validation were IL6ST, TNFRSF25, TNFSF8 and STAT1. The transcripts of the selected genes were increased in AS samples when compared to healthy donors. Relative expression levels were calculated for each sample after normalization against the housekeeping gene GAPDH. Experiments have been conducted in triplicates. Similar results were obtained using the housekeeping genes18s rRNA and beta-actin.](genes-08-00127-g001){#genes-08-00127-f001}

![Network analysis of differentially expressed genes (DEGs) in AS patients. (**A**) Protein-protein interaction (PPI) network of DEGs; (**B**) Degree Sorted Circle Layout of the PPI network. Nodes are ordered around a circle based on their degree of connectivity (number of edges). Nodes belonging to modules are highlighted in red; (**C**) Modules originated from the interaction network.](genes-08-00127-g002){#genes-08-00127-f002}

![Protein-protein interaction (PPI) network of DEGs in AS patients after treatment.](genes-08-00127-g003){#genes-08-00127-f003}

genes-08-00127-t001_Table 1

###### 

Genes modulated in Ankylosing spondylitis (AS) patients before treatment versus healthy controls.

  Probe Set ID                            *p* Value   Fold Change   Gene Symbol   Gene Title                                                                   Representative Public ID
  --------------------------------------- ----------- ------------- ------------- ---------------------------------------------------------------------------- --------------------------
  **Cell proliferation**                                                                                                                                       
  201367_s\_at                            0.001       13.9          ZFP36L2       ZFP36 ring finger protein-like 2                                             NM_006887
  203055_s\_at                            0.006       2.1           ARHGEF1       Rho guanine nucleotide exchange factor (GEF) 1                               NM_004706
  210541_s\_at                            0.014       1.7           TRIM27        tripartite motif containing 27                                               AF230394
  217202_s\_at                            0.011       2.4           GLUL          glutamate-ammonia ligase                                                     NM_002065
  201234_at                               0.001       2.0           ILK           integrin-linked kinase                                                       NM_004517
  210440_s\_at                            0.013       1.6           CDC14A        cell division cycle 14A                                                      AF064102
  **Extracellular matrix organization**                                                                                                                        
  202524_s\_at                            0.013       1.6           SPOCK2        sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2     NM_001134434
  205179_s\_at                            0.002       2.3           ADAM8         ADAM metallopeptidase domain 8                                               NM_001109
  216971_s\_at                            0.001       2.5           PLEC          plectin                                                                      Z54367
  216627_s\_at                            0.004       2.6           B4GALT1       UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1             U10473
  200001_at                               0.013       1.9           CAPNS1        calpain, small subunit 1                                                     NM_001749
  **Angiogenesis**                                                                                                                                             
  202509_s\_at                            \<0.001     1.6           TNFAIP2       tumor necrosis factor, alpha-induced protein 2                               XM_006720243
  201559_s\_at                            0.013       1.8           CLIC4         chloride intracellular channel 4                                             CR533501
  214931_s\_at                            0.002       1.6           SRPK2         SRSF protein kinase 2                                                        NM_001278273
  202434_s\_at                            0.003       1.8           CYP1B1        cytochrome P450, family 1, subfamily B, polypeptide 1                        NM_000104
  205179_s\_at                            0.002       2.3           ADAM8         ADAM metallopeptidase domain 8                                               NM_001109
  **Immune response**                                                                                                                                          
  207216_at                               0.003       1.7           TNFSF8        tumor necrosis factor (ligand) superfamily, member 8                         NM_001244
  214971_s\_at                            0.000       4.3           ST6GAL1       ST6 beta-galactosamide alpha-2,6-sialyltranferase 1                          NM_173216
  216901_s\_at                            0.000       13.6          IKZF1         IKAROS family zinc finger 1 (Ikaros)                                         NM_006060
  211861_x\_at                            0.002       3.5           CD28          CD28 molecule                                                                AF222343
  205456_at                               0.011       3.0           CD3E          CD3e molecule, epsilon (CD3-TCR complex)                                     NM_000733
  214551_s\_at                            0.009       3.5           CD7           CD7 molecule                                                                 NM_006137
  205831_at                               0.012       1.9           CD2           CD2 molecule                                                                 NM_001767
  207872_s\_at                            0.002       2.0           LILRA1        leukocyte immunoglobulin-like receptor, subfamily A, member 1                NM_006863
  208594_x\_at                            0.015       1.8           LILRA6        leukocyte immunoglobulin-like receptor, subfamily A, member 6                NM_024318
  205819_at                               0.003       −1.8          MARCO         macrophage receptor with collagenous structure                               NM_006770
  215339_at                               0.007       1.9           NKTR          natural killer-tumor recognition sequence                                    NM_005385
  208829_at                               0.008       1.5           TAPBP         TAP binding protein (tapasin)                                                AF029750
  209754_s\_at                            \<0.001     3.4           TMPO          thymopoietin                                                                 NM_003276
  206804_at                               0.005       1.8           CD3G          CD3g molecule, gamma (CD3-TCR complex)                                       NM_000073
  203547_at                               0.008       2.4           CD4           CD4 molecule                                                                 NM_000616
  205468_s\_at                            0.002       2.4           IRF5          interferon regulatory factor 5                                               NM_001098627
  203227_s\_at                            0.011       −1.5          TSPAN31       tetraspanin 31                                                               NM_005981
  202621_at                               0.002       2.2           IRF3          interferon regulatory factor 3                                               NM_001571
  210370_s\_at                            0.005       1.7           LY9           lymphocyte antigen 9                                                         AF244129
  214931_s\_at                            0.002       1.6           SRPK2         SRSF protein kinase 2                                                        NM_001278273
  216208_s\_at                            0.004       1.8           ATF6B         activating transcription factor 6 beta                                       NM_004381
  211574_s\_at                            \<0.001     2.5           CD46          CD46 molecule, complement regulatory protein                                 D84105
  211192_s\_at                            0.001       2.8           CD84          CD84 molecule                                                                AF054818
  210850_s\_at                            0.006       1.6           ELK1          ELK1, member of ETS oncogene family                                          AF000672
  210313_at                               0.012       −1.7          LILRA4        leukocyte immunoglobulin-like receptor, subfamily A, member 4                NM_012276
  200887_s\_at                            \<0.001     4.6           STAT1         signal transducer and activator of transcription 1                           GU211347
  204770_at                               0.009       1.8           TAP2          transporter 2, ATP-binding cassette                                          NM_000544
  206409_at                               0.007       1.8           TIAM1         T-cell lymphoma invasion and metastasis 1                                    NM_003253
  208602_x\_at                            \<0.001     3.8           CD6           CD6 molecule                                                                 NM_006725
  220132_s\_at                            0.004       2.8           CLEC2D        C-type lectin domain family 2, member D                                      NM_013269
  201835_s\_at                            \<0.001     1.8           PRKAB1        protein kinase, AMP-activated, beta 1                                        NM_006253
  204312_x\_at                            0.009       1.6           CREB1         cAMP responsive element binding protein 1                                    NM_004379
  221602_s\_at                            0.006       2.8           FAIM          Fas apoptotic inhibitory molecule                                            NM_001033030
  201234_at                               0.001       2.0           ILK           integrin-linked kinase                                                       NM_004517
  210796_x\_at                            0.010       1.6           SIGLEC6       sialic acid binding Ig-like lectin 6                                         D86359
  205026_at                               0.001       1.8           STAT5B        signal transducer and activator of transcription 5B                          NM_012448
  210298_x\_at                            0.010       1.8           FHL1          four and a half LIM domains 1                                                AF098518
  204864_s\_at                            0.003       3.2           IL6ST         interleukin 6 signal transducer                                              NM_002184
  201246_s\_at                            0.004       1.8           OTUB1         OTU domain, ubiquitin aldehyde binding 1                                     NM_017670
  203828_s\_at                            0.001       3.2           IL32          interleukin 32                                                               NM_004221
  **Inflammatory response**                                                                                                                                    
  208540_x\_at                            0.011       2.0           S100A11P1     S100 calcium binding protein A11 pseudogene 1                                NG_008400
  211968_s\_at                            0.004       1.6           HSP90AA1      heat shock protein 90kDa alpha (cytosolic), class A member 1                 NM_001017963
  211016_x\_at                            0.000       2.8           HSPA4         heat shock 70kDa protein 4                                                   BC002526
  200806_s\_at                            0.001       2.2           HSPD1         heat shock 60kDa protein 1 (chaperonin)                                      KU178141
  202626_s\_at                            0.004       −1.9          LYN           v-yes-1 Yamaguchi sarcoma viral related oncogene homolog                     NM_002350
  203085_s\_at                            0.005       2.5           TGFB1         transforming growth factor, beta 1                                           NM_000660
  203899_s\_at                            0.001       1.6           CRCP          CGRP receptor component                                                      NM_014478
  205179_s\_at                            0.002       2.3           ADAM8         ADAM metallopeptidase domain 8                                               NM_001109
  207163_s\_at                            0.007       1.6           AKT1          v-akt murine thymoma viral oncogene homolog 1                                XM_017021075
  210916_s\_at                            0.013       1.9           CD44          CD44 molecule (Indian blood group)                                           AF098641
  206341_at                               0.012       1.6           IL2RA         interleukin 2 receptor, alpha                                                NM_000417
  208376_at                               0.004       1.6           CCR4          chemokine (C-C motif) receptor 4                                             NM_005508
  211027_s\_at                            0.001       3.4           IKBKB         inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta   NM_001190720
  217489_s\_at                            0.002       2.6           IL6R          interleukin 6 receptor                                                       S72848
  **Interleukin-6 production**                                                                                                                                 
  200806_s\_at                            0.001       2.2           HSPD1         heat shock 60kDa protein 1 (chaperonin)                                      KU178141
  203331_s\_at                            0.005       1.6           INPP5D        inositol polyphosphate-5-phosphatase, 145kDa                                 U53470
  217489_s\_at                            0.002       2.6           IL6R          interleukin 6 receptor                                                       S72848
  201461_s\_at                            0.002       2.4           MAPKAPK2      mitogen-activated protein kinase-activated protein kinase 2                  NM_004759
  203388_at                               0.011       2.3           ARRB2         arrestin, beta 2                                                             NM_004313
  **Bone remodeling**                                                                                                                                          
  **(a) bone growth**                                                                                                                                          
  203085_s\_at                            0.005       2.52          TGFB1         transforming growth factor, beta 1                                           BC000125
  205485_at                               0.013       1.53          RYR1          ryanodine receptor 1 (skeletal)                                              NM_000540
  206788_s\_at                            0.003       1.72          CBFB          core-binding factor, beta subunit                                            AF294326
  207163_s\_at                            0.007       1.55          AKT1          v-akt murine thymoma viral oncogene homolog 1                                XM_017021075
  210671_x\_at                            0.006       1.70          MAPK8         mitogen-activated protein kinase 8                                           NM_001278548
  214326_x\_at                            0.007       3.88          JUND          jun D proto-oncogene                                                         NM_005354
  212105_s\_at                            0.000       4.8           DHX9          DEAH (Asp-Glu-Ala-His) box helicase 9                                        NM_001357
  207968_s\_at                            0.003       2.12          MEF2C         myocyte enhancer factor 2C                                                   NM_002397
  206788_s\_at                            0.003       1.72          CBFB          core-binding factor, beta subunit                                            AF294326
  216234_s\_at                            0.004       1.79          PRKACA        protein kinase, cAMP-dependent, catalytic, alpha                             M80335
  **(b) bone erosion**                                                                                                                                         
  214196_s\_at                            \<0.001     2.41          TPP1          tripeptidyl peptidase I                                                      NM_000391
  203331_s\_at                            0.005       1.57          INPP5D        inositol polyphosphate-5-phosphatase, 145 kDa                                U53470
  205179_s\_at                            0.002       2.31          ADAM8         ADAM metallopeptidase domain 8                                               NM_001109
  203395_s\_at                            0.002       −1.97         HES1          hairy and enhancer of split 1                                                NM_005524

genes-08-00127-t002_Table 2

###### 

Genes modulated in AS patients before treatment versus healthy controls grouped in signaling pathways.

  Probe Set ID                                      *p* Value   Fold Change   Gene Symbol   Gene Title                                                       Representative Public ID
  ------------------------------------------------- ----------- ------------- ------------- ---------------------------------------------------------------- --------------------------
  **Jak-Stat signaling pathway**                                                                                                                             
  200887_s\_at                                      \<0.001     4.61          STAT1         signal transducer and activator of transcription 1, 91 kDa       GU211347
  205026_at                                         0.001       1.82          STAT5B        signal transducer and activator of transcription 5B              NM_012448
  **Wnt signaling pathway**                                                                                                                                  
  214279_s\_at                                      0.011       1.89          NDRG2         NDRG family member 2                                             NM_201535
  217729_s\_at                                      0.004       2.29          AES           amino-terminal enhancer of split                                 NM_001130
  209456_s\_at                                      0.003       2.03          FBXW11        F-box and WD repeat domain containing 11                         AB033281
  209002_s\_at                                      0.004       1.94          CALCOCO1      calcium binding and coiled-coil domain 1                         NM_020898
  206562_s\_at                                      0.003       1.53          CSNK1A1       casein kinase 1, alpha 1                                         NM_001892
  205254_x\_at                                      0.007       2.57          TCF7          transcription factor 7 (T-cell specific, HMG-box)                NM_003202
  **MAPK cascade**                                                                                                                                           
  210671_x\_at                                      0.006       1.70          MAPK8         mitogen-activated protein kinase 8                               NM_001278548
  209952_s\_at                                      0.001       1.70          MAP2K7        mitogen-activated protein kinase kinase 7                        AF006689
  214786_at                                         0.001       1.96          MAP3K1        mitogen-activated protein kinase kinase kinase 1                 NM_005921
  211081_s\_at                                      0.004       2.44          MAP4K5        mitogen-activated protein kinase kinase kinase kinase 5          Z25426
  201461_s\_at                                      0.002       2.38          MAPKAPK2      mitogen-activated protein kinase-activated protein kinase 2      NM_004759
  210449_x\_at                                      0.005       1.79          MAPK14        mitogen-activated protein kinase 14                              NM_001315
  201979_s\_at                                      0.009       1.64          PPP5C         protein phosphatase 5, catalytic subunit                         NM_006247
  213490_s\_at                                      0.001       2.49          MAP2K2        mitogen-activated protein kinase kinase 2                        NM_030662
  207968_s\_at                                      0.003       2.12          MEF2C         myocyte enhancer factor 2C                                       NM_002397
  215220_s\_at                                      0.003       5.73          TPR           translocated promoter region, nuclear basket protein             NM_003292
  **Tumor necrosis factor-mediated signaling**                                                                                                               
  211282_x\_at                                      0.014       2.20          TNFRSF25      tumor necrosis factor receptor superfamily, member 25            AY254324
  209852_x\_at                                      0.003       1.69          PSME3         proteasome (prosome, macropain) activator subunit 3              BC001423
  200887_s\_at                                      0.000       4.61          STAT1         signal transducer and activator of transcription 1, 91 kDa       GU211347
  211027_s\_at                                      0.001       3.41          IKBKB         inhibitor of kappa light polypeptide gene enhancer in B-cells    NM_001190720
  **TLR signaling pathway**                                                                                                                                  
  210449_x\_at                                      0.005       1.79          MAPK14        mitogen-activated protein kinase 14                              NM_001315
  211027_s\_at                                      0.001       3.41          IKBKB         inhibitor of kappa light polypeptide gene enhancer in B-cells    NM_001190720
  215499_at                                         0.001       −1.55         MAP2K3        mitogen-activated protein kinase kinase 3                        GQ225578
  210671_x\_at                                      0.006       1.70          MAPK8         mitogen-activated protein kinase 8                               NM_001278548
  209878_s\_at                                      0.002       1.56          RELA          v-rel reticuloendotheliosis viral oncogene homolog A             M62399
  **Type I interferon signaling pathway**                                                                                                                    
  205468_s\_at                                      0.002       2.41          IRF5          interferon regulatory factor 5                                   NM_001098627
  202621_at                                         0.002       2.15          IRF3          interferon regulatory factor 3                                   NM_001571
  200887_s\_at                                      \<0.001     4.61          STAT1         signal transducer and activator of transcription 1, 91 kDa       GU211347
  211209_x\_at                                      0.004       1.60          SH2D1A        SH2 domain containing 1A                                         AF100540
  **Fibroblast growth factor receptor signaling**                                                                                                            
  213490_s\_at                                      0.001       2.49          MAP2K2        mitogen-activated protein kinase kinase 2                        NM_030662
  210655_s\_at                                      0.001       1.78          FOXO3         forkhead box O3                                                  AF041336
  216234_s\_at                                      0.004       1.79          PRKACA        protein kinase, cAMP-dependent, catalytic, alpha                 M80335
  213472_at                                         0.000       5.14          HNRNPH1       heterogeneous nuclear ribonucleoprotein H1 (H)                   NM_001257293
  **T-cell receptor signaling**                                                                                                                              
  207485_x\_at                                      0.004       1.65          BTN3A1        butyrophilin, subfamily 3, member A1                             NM_007048
  205285_s\_at                                      0.001       3.30          FYB           FYN binding protein                                              NM_001465
  204890_s\_at                                      0.010       1.69          LCK           lymphocyte-specific protein tyrosine kinase                      U07236
  206804_at                                         0.005       1.83          CD3G          CD3g molecule, gamma (CD3-TCR complex)                           NM_000073
  209671_x\_at                                      0.012       2.31          TRAC          T-cell receptor alpha constant                                   M12423
  **Small GTPase mediated signal transduction**                                                                                                              
  201469_s\_at                                      0.002       1.82          SHC1          Src homology 2 domain containing transforming protein 1          X68148
  213490_s\_at                                      0.001       2.49          MAP2K2        mitogen-activated protein kinase kinase 2                        NM_030662
  207419_s\_at                                      \<0.001     2.45          RAC2          ras-related C3 botulinum toxin substrate 2                       NM_002872
  208876_s\_at                                      0.001       1.81          PAK2          p21 protein (Cdc42/Rac)-activated kinase 2                       AF092132
  206341_at                                         0.012       1.58          IL2RA         interleukin 2 receptor, alpha                                    NM_000417
  204116_at                                         0.004       2.49          IL2RG         interleukin 2 receptor, gamma                                    NM_000206
  210317_s\_at                                      0.001       2.71          YWHAE         tyrosine 3-monooxygenase                                         U28936
  X00351_5\_at                                      0.003       2.65          ACTB          actin, beta                                                      NM_001101
  211108_s\_at                                      0.009       1.86          JAK3          Janus kinase 3                                                   U31601
  200641_s\_at                                      \<0.001     1.83          YWHAZ         tyrosine 3-monooxygenase                                         NM_003406
  216033_s\_at                                      0.001       1.87          FYN           FYN oncogene related to SRC, FGR, YES                            NM_002037
  **Transforming growth factor beta signaling**                                                                                                              
  203085_s\_at                                      0.005       2.52          TGFB1         transforming growth factor, beta 1                               NM_000660
  207334_s\_at                                      0.000       2.69          TGFBR2        transforming growth factor, beta receptor II (70/80 kDa)         NM_003242
  219543_at                                         0.012       −1.75         PBLD          phenazine biosynthesis-like protein domain containing            NM_022129
  211553_x\_at                                      0.013       1.70          APAF1         apoptotic peptidase activating factor 1                          AF149794
  200808_s\_at                                      0.004       2.60          ZYX           zyxin                                                            NM_003461
  204312_x\_at                                      0.009       1.62          CREB1         cAMP responsive element binding protein 1                        NM_004379
  **Phosphatidylinositol-mediated signaling**                                                                                                                
  217234_s\_at                                      0.003       2.51          EZR           ezrin                                                            NM_003379
  211230_s\_at                                      0.005       1.60          PIK3CD        phosphatidylinositol-4,5-bisphosphate 3-kinase                   U57843
  204890_s\_at                                      0.010       1.69          LCK           lymphocyte-specific protein tyrosine kinase                      U07236
  **Notch signaling**                                                                                                                                        
  215270_at                                         0.007       1.85          LFNG          LFNG O-fucosylpeptide 3-beta-*N*-acetylglucosaminyltransferase   U94354
  204152_s\_at                                      0.005       1.94          MFNG          MFNG O-fucosylpeptide 3-beta-*N*-acetylglucosaminyltransferase   NM_002405.3
  206341_at                                         0.012       1.58          IL2RA         interleukin 2 receptor, alpha                                    NM_000417

genes-08-00127-t003_Table 3

###### 

Pathways and biological processes that were enriched only pre- or post treatment.

  ----------------------------------------------------------- ------------------- -------------------------------------------------------------- -------------------
  **Enriched Pathways**                                                                                                                          
  **Pre-Treatment vs. Healthy Controls**                      ***p*** **Value**   **Post-Treatment vs. Healthy Controls**                        ***p*** **Value**
  Insulin/IGF pathway-protein kinase B signaling cascade      0.005               FAS signaling pathway                                          0.007
  Oxidative stress response                                   0.001               Histamine H2 receptor mediated signaling pathway               0.003
  p38 MAPK pathway                                            0.007               p53 pathway feedback loops 2                                   0.022
  p53 pathway                                                 0.008               Transcription regulation by bZIP transcription factor          0.042
  p53 pathway by glucose deprivation                          0.014               Heterotrimeric G-protein signaling pathway                     0.005
  P53 pathway feedback loops 1                                0.005                                                                              
  PI3 kinase pathway                                          0.015                                                                              
  Wnt signaling pathway                                       \<0.001                                                                            
  **Enriched Biological Processes**                                                                                                              
  **Pre-Treatment vs. Healthy Controls**                      ***p*** **Value**   **Post-Treatment vs. Healthy Controls**                        ***p*** **Value**
  ATP-dependent chromatin remodeling                          0.025               activation of protein kinase A activity                        \<0.001
  cytoskeleton organization                                   0.002               cellular response to oxidative stress                          0.010
  fibroblast growth factor receptor signaling pathway         \<0.001             extrinsic apoptotic signaling pathway in absence of ligand     0.007
  immune effector process                                     0.007               hematopoietic or lymphoid organ development                    0.037
  intrinsic apoptotic signaling pathway                       \<0.001             negative regulation of extrinsic apoptotic signaling pathway   \<0.001
  leukocyte migration                                         0.032               peptidyl-serine phosphorylation                                0.001
  negative regulation of protein phosphorylation              0.048               peptidyl-tyrosine phosphorylation                              \<0.001
  phosphatidylinositol-mediated signaling                     0.002               protein autophosphorylation                                    0.010
  positive regulation of cell differentiation                 0.004               Ras protein signal transduction                                0.001
  positive regulation of gene expression                      0.019               regulation of lymphocyte activation                            0.026
  positive regulation of interleukin-2 biosynthetic process   0.003               regulation of mitochondrial membrane permeability              0.039
  positive regulation of T-cell proliferation                 0.035               regulation of myeloid cell differentiation                     0.004
  regulation of execution phase of apoptosis                  0.045                                                                              
  regulation of leukocyte mediated immunity                   0.005                                                                              
  regulation of lymphocyte differentiation                    0.017                                                                              
  response to interleukin-2                                   0.001                                                                              
  response to mechanical stimulus                             0.004                                                                              
  small GTPase mediated signal transduction                   0.040                                                                              
  T-cell costimulation                                        \<0.001                                                                            
  T-cell differentiation                                      0.015                                                                              
  T-cell homeostasis                                          0.004                                                                              
  T-cell receptor signaling pathway                           \<0.001                                                                            
  ----------------------------------------------------------- ------------------- -------------------------------------------------------------- -------------------

genes-08-00127-t004_Table 4

###### 

Molecular signalings in which are involved genes modulated only before treatment.

  Patients Group 1                                                    Patients Group 2
  ------------------------------------------------------------------- ---------------------------------------
  Immune response                                                     Immune response
  Angiogenesis                                                        Angiogenesis
  Inflammation                                                        Inflammation
  G-protein coupled receptor signaling                                G-protein coupled receptor signaling
  Jak-Stat signaling                                                  Jak-Stat signaling
  MAP kinase cascade                                                  MAP kinase cascade
  Notch signaling                                                     Notch signaling
  PDGF receptor signaling                                             PDGF receptor signaling
  Small GTPase signaling                                              Small GTPase signaling
  T-cell receptor signaling                                           T-cell receptor signaling
  TGF beta signaling                                                  TGF beta signaling
  Intreleukin 6 production                                            EGF receptor signaling
  Adenylate cyclase-modulating G-protein coupled receptor signaling   Ephrin receptor signaling
  Chemokine mediated signaling                                        Fc-gamma receptor signaling
  Cytokine mediated signaling                                         Integrin-mediated signaling pathway
  Endothelin signaling                                                Interleukin signaling
  Heterotrimeric G-protein signaling                                  Positive regulation of BMP signaling
  Intrinsic apoptotic signaling in response to DNA damage signaling   Positive regulation of VEGF signaling
  NIK/NF-Kappa B signaling                                            
  Protein kinase B signaling                                          
  Stimulatory c-type lectin receptor signaling                        
  Toll-like receptor signaling                                        
  Tumor necrosis factor signaling                                     
  Type 1 interferon signaling                                         
  Wnt signaling                                                       

genes-08-00127-t005_Table 5

###### 

Genes modulated only before treatment in AS patients group 1. n.c.: not changed.

  Probe Set ID                                    *p* Value   FC Pre   FC Post   Gene Symbol   Gene Title                                                                          Representative Public ID
  ----------------------------------------------- ----------- -------- --------- ------------- ----------------------------------------------------------------------------------- --------------------------
  **Immune response**                                                                                                                                                              
  207794_at                                       0.015       5.05     n.c.      CCR2          chemokine (C-C motif) receptor 2                                                    NM_000648
  216033_s\_at                                    0.013       1.70     n.c.      FYN           FYN proto-oncogene, Src family tyrosine kinase                                      S74774
  208965_s\_at                                    0.003       2.87     n.c.      IFI16         interferon, gamma-inducible protein 16                                              BG256677
  200806_s\_at                                    0.004       2.62     n.c.      HSPD1         heat shock 60kDa protein 1 (chaperonin)                                             BE256479
  211210_x\_at                                    0.015       1.53     n.c.      SH2D1A        SH2 domain containing 1A                                                            AF100539
  210541_s\_at                                    \<0.001     2.21     n.c.      TRIM27        tripartite motif containing 27                                                      AF230394
  221092_at                                       0.007       4.53     n.c.      IKZF3         IKAROS family zinc finger 3 (Aiolos)                                                NM_012481
  202643_s\_at                                    0.003       −4.55    n.c.      TNFAIP3       tumor necrosis factor, alpha-induced protein 3                                      AI738896
  219994_at                                       0.009       1.72     n.c.      APBB1IP       amyloid beta precursor protein-binding, B, 1 interacting protein                    NM_019043
  220363_s\_at                                    0.012       1.79     n.c.      ELMO2         engulfment and cell motility 2                                                      NM_022086
  204506_at                                       0.009       1.50     n.c.      PPP3R1        protein phosphatase 3, regulatory subunit B, alpha                                  AL544951
  **Inflammatory response**                                                                                                                                                        
  201883_s\_at                                    0.001       −2.05    n.c.      B4GALT1       beta 1,4- galactosyltransferase, polypeptide 1                                      D29805
  207794_at                                       0.015       5.05     n.c.      CCR2          chemokine (C-C motif) receptor 2                                                    NM_000648
  214370_at                                       0.007       1.91     n.c.      S100A8        S100 calcium binding protein A8                                                     AW238654
  200808_s\_at                                    0.002       2.02     n.c.      ZYX           zyxin                                                                               NM_003461
  210218_s\_at                                    0.002       2.50     n.c.      SP100         SP100 nuclear antigen                                                               U36501
  205760_s\_at                                    0.011       1.62     n.c.      OGG1          8-oxoguanine DNA glycosylase                                                        NM_016821
  209545_s\_at                                    0.011       −1.95    n.c.      RIPK2         receptor-interacting serine-threonine kinase 2                                      AF027706
  202742_s\_at                                    0.011       1.91     n.c.      PRKACB        protein kinase, cAMP-dependent, catalytic, beta                                     NM_002731
  204280_at                                       0.005       1.53     n.c.      RGS14         regulator of G-protein signaling 14                                                 NM_006480
  203927_at                                       0.003       −1.83    n.c.      NFKBIE        nuclear factor of k light polypeptide gene enhancer in B-cells inhibitor, epsilon   NM_004556
  205727_at                                       0.015       −1.68    n.c.      TEP1          telomerase-associated protein 1                                                     NM_007110
  **Angiogenesis**                                                                                                                                                                 
  212723_at                                       0.012       −2.14    n.c.      JMJD6         jumonji domain containing 6                                                         AK021780
  213844_at                                       0.014       −2.13    n.c.      HOXA5         homeobox A5                                                                         NM_019102
  211561_x\_at                                    0.006       1.91     n.c.      MAPK14        mitogen-activated protein kinase 14                                                 L35253
  201883_s\_at                                    0.001       −2.05    n.c.      B4GALT1       beta 1,4- galactosyltransferase, polypeptide 1                                      D29805
  **TNF signaling pathway**                                                                                                                                                        
  207794_at                                       0.015       5.05     n.c.      CCR2          chemokine (C-C motif) receptor 2                                                    NM_000648
  222142_at                                       0.011       −1.82    n.c.      CYLD          cylindromatosis (turban tumor syndrome)                                             AK024212
  202643_s\_at                                    0.003       −4.55    n.c.      TNFAIP3       tumor necrosis factor, alpha-induced protein 3                                      AI738896
  **Type 1 interferon signaling**                                                                                                                                                  
  210218_s\_at                                    0.002       2.50     n.c.      SP100         SP100 nuclear antigen                                                               U36501
  208965_s\_at                                    0.003       2.87     n.c.      IFI16         interferon, gamma-inducible protein 16                                              BG256677
  200806_s\_at                                    0.004       2.62     n.c.      HSPD1         heat shock 60kDa protein 1 (chaperonin)                                             BE256479
  222142_at                                       0.011       −1.82    n.c.      CYLD          cylindromatosis (turban tumor syndrome)                                             AK024212
  202643_s\_at                                    0.003       −4.55    n.c.      TNFAIP3       tumor necrosis factor, alpha-induced protein 3                                      AI738896
  221287_at                                       0.010       1.50               RNASEL        ribonuclease L (2′,5′-oligoisoadenylate synthetase-dependent)                       NM_021133
  **IL6 production**                                                                                                                                                               
  207794_at                                       0.015       5.05     n.c.      CCR2          chemokine (C-C motif) receptor 2                                                    NM_000648
  200806_s\_at                                    0.004       2.62     n.c.      HSPD1         heat shock 60kDa protein 1 (chaperonin)                                             BE256479
  **Toll like receptor signaling pathway**                                                                                                                                         
  200598_s\_at                                    0.011       1.54     n.c.      HSP90B1       heat shock protein 90kDa beta (Grp94), member 1                                     AI582238
  200806_s\_at                                    0.004       2.62     n.c.      HSPD1         heat shock 60kDa protein 1 (chaperonin)                                             BE256479
  211561_x\_at                                    0.006       1.91     n.c.      MAPK14        mitogen-activated protein kinase 14                                                 L35253
  **Jak-Stat signaling pathway**                                                                                                                                                   
  205026_at                                       0.005       1.85     n.c.      STAT5B        signal transducer and activator of transcription 5B                                 NM_012448
  211561_x\_at                                    0.006       1.91     n.c.      MAPK14        mitogen-activated protein kinase 14                                                 L35253
  **Wnt signaling pathway**                                                                                                                                                        
  208074_s\_at                                    0.008       1.50     n.c.      AP2S1         adaptor-related protein complex 2, sigma 1 subunit                                  NM_021575
  204506_at                                       0.009       1.50     n.c.      PPP3R1        protein phosphatase 3, regulatory subunit B, alpha                                  AL544951
  201868_s\_at                                    0.012       2.29     n.c.      TBL1X         transducin (beta)-like 1X-linked                                                    NM_005647
  203506_s\_at                                    0.014       1.80     n.c.      MED12         mediator complex subunit 12                                                         NM_005120
  209383_at                                       0.006       −2.32    n.c.      DDIT3         DNA-damage-inducible transcript 3                                                   BC003637
  213710_s\_at                                    0.014       1.59     n.c.      CALM1         calmodulin 1 (phosphorylase kinase, delta)                                          AL523275
  206409_at                                       0.009       1.99     n.c.      TIAM1         T-cell lymphoma invasion and metastasis 1                                           NM_003253
  213579_s\_at                                    0.008       −1.51    n.c.      EP300         E1A binding protein p300                                                            AI459462
  210649_s\_at                                    0.004       2.81     n.c.      ARID1A        AT rich interactive domain 1A (SWI-like)                                            AF231056
  211300_s\_at                                    0.009       3.08     n.c.      TP53          tumor protein p53                                                                   K03199
  **MAPK cascade**                                                                                                                                                                 
  210622_x\_at                                    0.012       1.63     n.c.      CDK10         cyclin-dependent kinase 10                                                          AF153430
  213710_s\_at                                    0.014       1.59     n.c.      CALM1         calmodulin 1 (phosphorylase kinase, delta)                                          AL523275
  209457_at                                       0.013       −2.95    n.c.      DUSP5         dual specificity phosphatase 5                                                      U16996
  211561_x\_at                                    0.006       1.91     n.c.      MAPK14        mitogen-activated protein kinase 14                                                 L35253
  216033_s\_at                                    0.013       1.70     n.c.      FYN           FYN proto-oncogene, Src family tyrosine kinase                                      S74774
  **Small Gtpase mediated signal transduction**                                                                                                                                    
  205461_at                                       \<0.001     2.98     n.c.      RAB35         RAB35, member RAS oncogene family                                                   NM_006861
  219842_at                                       0.011       1.50     n.c.      ARL15         ADP-ribosylation factor-like 15                                                     NM_019087
  209051_s\_at                                    0.001       1.58     n.c.      RALGDS        ral guanine nucleotide dissociation stimulator                                      AF295773
  211622_s\_at                                    0.001       1.80     n.c.      ARF3          ADP-ribosylation factor 3                                                           M33384
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###### 

Genes modulated only before treatment in AS patients-group 2. n.c.: not changed.

  Probe Set ID                           *p* Value   FC Pre   FC Post   Gene Symbol   Gene Title                                                       Representative Public ID
  -------------------------------------- ----------- -------- --------- ------------- ---------------------------------------------------------------- --------------------------
  **Immune response**                                                                                                                                  
  214450_at                              0.011       2.52     n.c.      CTSW          cathepsin W                                                      NM_001335
  206082_at                              0.007       1.60     n.c.      HCP5          HLA complex P5 (non-protein coding)                              NR_040662
  216542_x\_at                           0.007       1.50     n.c.      IGHA1         immunoglobulin heavy constant alpha 1                            AJ275355
  208071_s\_at                           0.011       1.50     n.c.      LAIR1         leukocyte-associated immunoglobulin-like receptor 1              NM_002287
  217513_at                              0.005       −1.65    n.c.      MILR1         mast cell immunoglobulin-like receptor 1                         NM_001085423
  208759_at                              0.011       1.50     n.c.      NCSTN         nicastrin                                                        AF240468
  206804_at                              0.011       1.91     n.c.      CD3G          CD3g molecule, gamma (CD3-TCR complex)                           NM_000073
  211373_s\_at                           0.012       −1.51    n.c.      PSEN2         presenilin 2                                                     NM_000447
  210479_s\_at                           0.008       1.79     n.c.      RORA          RAR-related orphan receptor A                                    NM_134261
  209151_x\_at                           0.005       1.54     n.c.      TCF3          transcription factor 3                                           NM_003200
  **Inflammatory response**                                                                                                                            
  217119_s\_at                           0.003       1.50     n.c.      CXCR3         chemokine (C-X-C motif) receptor 3                               NM_001504
  201348_at                              0.005       1.63     n.c.      GPX3          glutathione peroxidase 3 (plasma)                                NM_002084
  207075_at                              0.012       −1.80    n.c.      NLRP3         NLR family, pyrin domain containing 3                            NM_004895
  **Angiogenesis**                                                                                                                                     
  216689_x\_at                           0.005       1.60     n.c.      ARHGAP1       Rho GTPase activating protein 1                                  NM_004308
  208937_s\_at                           0.013       −1.87    n.c.      ID1           inhibitor of DNA binding 1                                       D13889
  204626_s\_at                           0.006       1.62     n.c.      ITGB3         integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)      NM_000212
  **MAPK cascade**                                                                                                                                     
  210787_s\_at                           0.014       1.87     n.c.      CAMKK2        calcium/calmodulin-dependent protein kinase kinase 2, beta       AF140507
  214786_at                              0.003       1.77     n.c.      MAP3K1        mitogen-activated protein kinase kinase kinase 1                 NM_005921
  **Jak-stat signaling pathway**                                                                                                                       
  217199_s\_at                           0.015       1.54     n.c.      STAT2         signal transducer and activator of transcription 2, 113kDa       S81491
  210995_s\_at                           0.011       1.55     n.c.      TRIM23        tripartite motif containing 23                                   AF230399
  **Small GTPase signal transduction**                                                                                                                 
  216689_x\_at                           0.005       1.60     n.c.      ARHGAP1       Rho GTPase activating protein 1                                  NM_004308
  218884_s\_at                           0.002       1.51     n.c.      GUF1          GUF1 GTPase homolog (S. cerevisiae)                              NM_021927
  209051_s\_at                           0.003       1.65     n.c.      RALGDS        ral guanine nucleotide dissociation stimulator                   AF295773
  **TCR signaling pathway**                                                                                                                            
  206804_at                              0.011       1.91     n.c.      CD3G          CD3g molecule, gamma (CD3-TCR complex)                           NM_000073
  211373_s\_at                           0.012       −1.51    n.c.      PSEN2         presenilin 2                                                     NM_000447
  219724_s\_at                           0.012       2.07     n.c.      TESPA1        thymocyte expressed, positive selection associated 1             NM_014796
  211902_x\_at                           0.010       2.06     n.c.      YME1L1        YME1-like 1 ATPase                                               NM_139312
  **TGFB signaling pathway**                                                                                                                           
  221235_s\_at                           0.004       −1.50    n.c.      TGFBRAP1      transforming growth factor, beta receptor associated protein 1   NM_004257
  205187_at                              0.006       1.60     n.c.      SMAD5         SMAD family member 5                                             AF010601
  214786_at                              0.003       1.77     n.c.      MAP3K1        mitogen-activated protein kinase kinase kinase 1                 NM_005921
  203988_s\_at                           0.008       1.64     n.c.      FUT8          fucosyltransferase 8 (alpha (1,6) fucosyltransferase)            NM_004480
  **Notch signaling pathway**                                                                                                                          
  203988_s\_at                           0.008       1.64     n.c.      FUT8          fucosyltransferase 8 (alpha (1,6) fucosyltransferase)            NM_004480
  208759_at                              0.011       1.50     n.c.      NCSTN         nicastrin                                                        AF240468
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###### 

Biological processes that were significantly enriched in genes corrected by the treatment.

  AS Patients-Group 1                                                                         AS Patients-Group 2                                                  
  ------------------------------------------------------------------------------------------- --------------------- ---------------------------------------------- -------
  activation of immune response                                                               0.014                 leukocyte activation                           0.034
  positive regulation of immune system process                                                0.002                 lymphocyte activation                          0.050
  positive regulation of leukocyte activation                                                 0.005                 T-cell activation                              0.038
  positive regulation of lymphocyte activation                                                0.002                 positive regulation of B-cell activation       0.015
  positive regulation of lymphocyte proliferation                                             0.023                 NLRP3 inflammasome complex assembly            0.006
  lymphocyte activation involved in immune response                                           0.046                 angiogenesis                                   0.002
  T-cell activation                                                                           0.005                 response to transforming growth factor beta    0.010
  positive regulation of T-cell activation                                                    0.005                 G-protein coupled receptor signaling pathway   0.031
  cellular response to unfolded protein                                                       0.001                                                                
  positive regulation of B-cell activation                                                    0.041                                                                
  B-cell cytokine production                                                                  0.024                                                                
  inflammatory response                                                                       0.026                                                                
  response to oxidative stress                                                                0.022                                                                
  positive regulation of cytokine production                                                  0.012                                                                
  positive regulation of type I interferon production                                         0.017                                                                
  toll-like receptor signaling pathway                                                        0.039                                                                
  positive regulation of interleukin-2 production                                             0.001                                                                
  regulation of adaptive immune response based on somatic recombination of immune receptors   0.013                                                                

[^1]: These authors contributed equally to this work.
